An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe

Denis Horgan, Marleen Jansen, Lada Leyens, Jonathan A. Lal, Ralf Sudbrak, Erica Hackenitz, Ulrike Bußhoff, Wolfgang Ballensiefen, Angela Brand

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Personalised medicine (PM) is an innovative way to produce better patient outcomes by using an individualised or stratified approach to disease and treatment rather than a collective treatment approach for patients. Despite its tangible advantages, the complex process to translate PM into the member states and European healthcare systems has delayed its uptake. The aim of this study is to identify relevant barriers represented by an index to summarise challenging areas for the implementation of PM in Europe. Methods: A systematic literature review was conducted, and a gaps-and-needs assessment together with a strengths-weaknesses-opportunities-and-threats analysis were applied to review strategic reports and conduct interviews with key stakeholders. Furthermore, surveys were sent out to representatives of stakeholder groups. The index was constructed based on the priorisation of relevant factors by stakeholders. Results: A need for stakeholder-agreed standards at all levels of implementation of PM exists, from validating biomarkers to definitions of 'informed consent'. The barriers to implement PM are identified in 7 areas, namely, stakeholder involvement, standardisation, interoperable infrastructure, European-level policy making, funding, data and research, and healthcare systems. Conclusions: Challenges in the above-mentioned areas can and must be successfully tackled if we are to create a healthier Europe through PM. In order to create an environment in which PM can thrive for the patients' best outcomes, there is an urgent need for systematic actions to remove as many barriers as possible.

Original languageEnglish
Pages (from-to)287-298
Number of pages12
JournalPublic Health Genomics
Volume17
DOIs
Publication statusPublished - 25-12-2014

Fingerprint

Precision Medicine
Pharmacogenetics
Delivery of Health Care
Needs Assessment
Policy Making
Informed Consent
Information Systems
Biomarkers
Interviews
Therapeutics
Research

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health
  • Genetics(clinical)

Cite this

Horgan, Denis ; Jansen, Marleen ; Leyens, Lada ; Lal, Jonathan A. ; Sudbrak, Ralf ; Hackenitz, Erica ; Bußhoff, Ulrike ; Ballensiefen, Wolfgang ; Brand, Angela. / An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe. In: Public Health Genomics. 2014 ; Vol. 17. pp. 287-298.
@article{e3cbe315e2b949e08b5632d2de8d779b,
title = "An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe",
abstract = "Background: Personalised medicine (PM) is an innovative way to produce better patient outcomes by using an individualised or stratified approach to disease and treatment rather than a collective treatment approach for patients. Despite its tangible advantages, the complex process to translate PM into the member states and European healthcare systems has delayed its uptake. The aim of this study is to identify relevant barriers represented by an index to summarise challenging areas for the implementation of PM in Europe. Methods: A systematic literature review was conducted, and a gaps-and-needs assessment together with a strengths-weaknesses-opportunities-and-threats analysis were applied to review strategic reports and conduct interviews with key stakeholders. Furthermore, surveys were sent out to representatives of stakeholder groups. The index was constructed based on the priorisation of relevant factors by stakeholders. Results: A need for stakeholder-agreed standards at all levels of implementation of PM exists, from validating biomarkers to definitions of 'informed consent'. The barriers to implement PM are identified in 7 areas, namely, stakeholder involvement, standardisation, interoperable infrastructure, European-level policy making, funding, data and research, and healthcare systems. Conclusions: Challenges in the above-mentioned areas can and must be successfully tackled if we are to create a healthier Europe through PM. In order to create an environment in which PM can thrive for the patients' best outcomes, there is an urgent need for systematic actions to remove as many barriers as possible.",
author = "Denis Horgan and Marleen Jansen and Lada Leyens and Lal, {Jonathan A.} and Ralf Sudbrak and Erica Hackenitz and Ulrike Bu{\ss}hoff and Wolfgang Ballensiefen and Angela Brand",
year = "2014",
month = "12",
day = "25",
doi = "10.1159/000368034",
language = "English",
volume = "17",
pages = "287--298",
journal = "Public Health Genomics",
issn = "1662-4246",
publisher = "S. Karger AG",

}

Horgan, D, Jansen, M, Leyens, L, Lal, JA, Sudbrak, R, Hackenitz, E, Bußhoff, U, Ballensiefen, W & Brand, A 2014, 'An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe', Public Health Genomics, vol. 17, pp. 287-298. https://doi.org/10.1159/000368034

An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe. / Horgan, Denis; Jansen, Marleen; Leyens, Lada; Lal, Jonathan A.; Sudbrak, Ralf; Hackenitz, Erica; Bußhoff, Ulrike; Ballensiefen, Wolfgang; Brand, Angela.

In: Public Health Genomics, Vol. 17, 25.12.2014, p. 287-298.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe

AU - Horgan, Denis

AU - Jansen, Marleen

AU - Leyens, Lada

AU - Lal, Jonathan A.

AU - Sudbrak, Ralf

AU - Hackenitz, Erica

AU - Bußhoff, Ulrike

AU - Ballensiefen, Wolfgang

AU - Brand, Angela

PY - 2014/12/25

Y1 - 2014/12/25

N2 - Background: Personalised medicine (PM) is an innovative way to produce better patient outcomes by using an individualised or stratified approach to disease and treatment rather than a collective treatment approach for patients. Despite its tangible advantages, the complex process to translate PM into the member states and European healthcare systems has delayed its uptake. The aim of this study is to identify relevant barriers represented by an index to summarise challenging areas for the implementation of PM in Europe. Methods: A systematic literature review was conducted, and a gaps-and-needs assessment together with a strengths-weaknesses-opportunities-and-threats analysis were applied to review strategic reports and conduct interviews with key stakeholders. Furthermore, surveys were sent out to representatives of stakeholder groups. The index was constructed based on the priorisation of relevant factors by stakeholders. Results: A need for stakeholder-agreed standards at all levels of implementation of PM exists, from validating biomarkers to definitions of 'informed consent'. The barriers to implement PM are identified in 7 areas, namely, stakeholder involvement, standardisation, interoperable infrastructure, European-level policy making, funding, data and research, and healthcare systems. Conclusions: Challenges in the above-mentioned areas can and must be successfully tackled if we are to create a healthier Europe through PM. In order to create an environment in which PM can thrive for the patients' best outcomes, there is an urgent need for systematic actions to remove as many barriers as possible.

AB - Background: Personalised medicine (PM) is an innovative way to produce better patient outcomes by using an individualised or stratified approach to disease and treatment rather than a collective treatment approach for patients. Despite its tangible advantages, the complex process to translate PM into the member states and European healthcare systems has delayed its uptake. The aim of this study is to identify relevant barriers represented by an index to summarise challenging areas for the implementation of PM in Europe. Methods: A systematic literature review was conducted, and a gaps-and-needs assessment together with a strengths-weaknesses-opportunities-and-threats analysis were applied to review strategic reports and conduct interviews with key stakeholders. Furthermore, surveys were sent out to representatives of stakeholder groups. The index was constructed based on the priorisation of relevant factors by stakeholders. Results: A need for stakeholder-agreed standards at all levels of implementation of PM exists, from validating biomarkers to definitions of 'informed consent'. The barriers to implement PM are identified in 7 areas, namely, stakeholder involvement, standardisation, interoperable infrastructure, European-level policy making, funding, data and research, and healthcare systems. Conclusions: Challenges in the above-mentioned areas can and must be successfully tackled if we are to create a healthier Europe through PM. In order to create an environment in which PM can thrive for the patients' best outcomes, there is an urgent need for systematic actions to remove as many barriers as possible.

UR - http://www.scopus.com/inward/record.url?scp=84911493416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911493416&partnerID=8YFLogxK

U2 - 10.1159/000368034

DO - 10.1159/000368034

M3 - Article

C2 - 25401385

AN - SCOPUS:84911493416

VL - 17

SP - 287

EP - 298

JO - Public Health Genomics

JF - Public Health Genomics

SN - 1662-4246

ER -